On April 18, 2023 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that the company presented a poster on ATOR-4066, a Neo-X-Prime bispecific antibody (bsAb), at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida (Press release, Alligator Bioscience, APR 18, 2023, View Source [SID1234630223]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation, entitled "ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo", highlights how ATOR-4066 has the potential to induce strong anti-tumor responses in patients with carcinoembryonic antigen 5 (CEACAM5)-expressing tumors.
CEACAM5, a well described clinical target for cancer therapy, is a glycoprotein that is overexpressed on the cell surface of many cancers including colorectal, gastric, pancreatic, and non-small cell lung cancer, with limited expression in normal adult tissue. Thus, it is an ideal target for a tumor-directed bispecific conditional CD40 agonist like ATOR-4066.
The data demonstrate CEACAM5 expression in relevant indications and how ATOR-4066 induces:
CEACAM5-conditional CD40-activation of tumor-infiltrating immune cells in patient-derived dissociated tumor samples from indications with high CEACAM5 expression, including colorectal and gastric cancer
co-localization of CEACAM5-expressing tumor debris and CD40-expressing antigen presenting cells
strong in vivo anti-tumor efficacy and induction of immunological memory
"We are excited to be presenting new data from our novel Neo-X-Prime approach at this year’s AACR (Free AACR Whitepaper) meeting," said Søren Bregenholt, CEO of Alligator Bioscience. "We have already shown that simultaneously targeting CD40 and tumor associated antigens leads to superior anti-tumor immunity. These new data further demonstrate the ability of ATOR-4066 to remodel the immune microenvironment and, as it continues to show great potential in inducing strong anti-tumor responses in CEACAM5-expressing tumors, we remain committed to advancing ATOR-4066 towards the clinic."
Poster Presentation Details
Abstract Number: 2939
Title: ATOR-4066, a Neo-X-Primebispecific antibody targeting CD40 and CEO, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
Date/Time: Monday 17 April, 2023, 1.30 – 5.00 pm EDT
Session: PO.IM01.12 – Therapeutic Antibodies 2
Presenter: Anette Sundstedt, Principal Scientist, Alligator Bioscience
Location: Orange County Convention Center, Poster Section 23, Poster Board 2939